---
schema_version: "secwatch.filing_event.v1"
accession: "0001798749-23-000023"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2023-04-05T23:59:59+00:00"
generated_at: "2026-06-17T05:58:05.375660+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aerovate Therapeutics enters into $75M ATM equity offering with BofA Securities

## Summary
- Entered into ATM Sales Agreement with BofA Securities to sell up to $75M of common stock.
- Shares sold at market prices; BofA receives 3% commission on gross proceeds.
- Company not obligated to sell any shares; may suspend or terminate offering at any time.
- Offering made under existing effective shelf registration statement on Form S-3.

## SEC filing metadata
- accession: 0001798749-23-000023
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2023-04-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000179874923000023/0001798749-23-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000179874923000023/tmb-20230405x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001798749-23-000023
- JSON: https://secwatch.observer/filing/0001798749-23-000023.json
- Plain text: https://secwatch.observer/filing/0001798749-23-000023.txt

## Key facts
- Material Agreements
  Jade Biosciences, Inc. entered into ATM Equity Offering SM Sales Agreement with BofA Securities, Inc. valued at up to $75,000,000 (effective 2023-04-05).
  - Action: entry
  - Agreement: atm program
  - Counterparty: BofA Securities, Inc.
  - Value: up to $75,000,000
  - Effective: 2023-04-05
  source text: On April 5, 2023, Aerovate Therapeutics, Inc. (the “Company”) entered into an ATM Equity Offering SM Sales Agreement (the “Sales Agreement”), with BofA Securities, Inc. (“BofA”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $75,000,000 (the “Shares”) through BofA as its sales agent or to BofA as principal for its own account.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1798749/000179874923000023/0001798749-23-000023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.